NASD · Healthcare · Biotechnology · USA
Vericel Corp is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Vericel Corporation develops cell therapy and specialty biologic products for sports medicine and severe burn care. The company markets MACI, an autologous cell therapy for knee cartilage repair, Epicel for severe burns, and NexoBrid, a topical burn treatment licensed from MediWound. These products serve orthopedic surgeons and burn care centers in the United States.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Vericel Corp stock.
Overvalued: intrinsic value $13.68 per share, market price $57.88, margin of safety -323.0% (as of 2026-11-17).
Discounting its cash flows at 9.7% (average of 2 methods) values the shares at $13.68; the price of $57.88 is 323% above that value.
17 more funds hold it; the full list is part of the paid plan.
77 more in this industry show a wider margin of safety.
VCEL is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 9.7% (average of 2 methods) values the shares at $13.68; the price of $57.88 is 323% above that value.
$13.68 per share (as of the 2026-11-17 close), against a market price of $57.88. That is a margin of safety of -323.0%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.